Spero Therapeutics Inc (NAS:SPRO)
$ 1.03 0.0861 (9.12%) Market Cap: 56.15 Mil Enterprise Value: -20.21 Mil PE Ratio: 12.88 PB Ratio: 0.85 GF Score: 39/100

Spero Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 15, 2019 / 11:35PM GMT
Release Date Price: $11.92 (-8.24%)
Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research

Thank you for joining me -- us. My name is Jason Gerberry; I'm the U.S. pharma analyst at Bank of America. I'm pleased to be introducing our next company presenter, Spero Therapeutics CEO, Ankit Mahadevia. Ankit has a presentation, and I'm going to turn the podium over to him.

Ankit Mahadevia
Spero Therapeutics, Inc. - Co-Founder, CEO, President & Director

Great. Thanks to Jason, and to you (inaudible) the BofA team for inviting us to the conference. We appreciate the opportunity to present.

So I'll start our presentation with a story, and most importantly, our patients tell us where we should be directing our pipeline for medicines. And [Timothy Mark], who was a sufferer of a urinary tract infection was kind enough to share his story with all of us, and [Tim's] a man after my own heart. He was a -- in medical training doing a way rotation basically or auditioning for your potential future employers. He was doing a way rotation in Maryland and probably during

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot